Bristol Myers Squibb raises 2025 guidance after strong Q1 earnings, driven by growth portfolio and foreign exchange gains.
The US Supreme Court weighs Trump's request to reinstate a controversial transgender troops ban, as legal battles continue over the policy's impact on military readiness and transgender rights.
Bristol Myers Squibb raises 2025 guidance after strong Q1 earnings, driven by growth portfolio and foreign exchange gains.
The US Supreme Court weighs Trump's request to reinstate a controversial transgender troops ban, as legal battles continue over the policy's impact on military readiness and transgender rights.